Deubiquitinating enzymes as oncotargets

Oncotarget

Volumn 6, Issue 12, 2015, Pages 9657-9668

  McClurg, Urszula L ^a   Robson, Craig N ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Androgen receptor; Cancer; Chromatin; Deubiquitination; DUBS; Epigenetics; Histones

Indexed keywords

2 [4 [2 [3 CYCLOHEXYL 1 (4 CYCLOHEXYLBUTYL)UREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; BORTEZOMIB; CISPLATIN; DEUBIQUITINASE; PIMOZIDE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; USP1 PROTEIN; USP7 PROTEIN; WD40 PROTEIN; CHROMATIN; DNA; HISTONE; NUCLEAR PROTEIN; PROTEIN BINDING; UBIQUITIN THIOLESTERASE; USP1 ASSOCIATED FACTOR 1, HUMAN; USP1 PROTEIN, HUMAN; USP7 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL CYCLE REGULATION; DEUBIQUITINATION; DNA DAMAGE; DNA REPAIR; DRUG DESIGN; DRUG TARGETING; ENZYME ACTIVITY; EPIGENETICS; HISTONE MODIFICATION; HUMAN; MULTIPLE MYELOMA; NONHUMAN; UBIQUITINATION; ANIMAL; CANCER TRANSPLANTATION; CELL CYCLE; CHEMISTRY; CHROMATIN; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; METABOLISM; METASTASIS; MOUSE; NEOPLASMS; PROTEIN PROCESSING;

ANIMALS; CELL CYCLE; CHROMATIN; DNA; DNA DAMAGE; DNA REPAIR; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; MICE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOPLASMS; NUCLEAR PROTEINS; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; TRANSCRIPTION FACTORS; UBIQUITIN THIOLESTERASE; UBIQUITIN-SPECIFIC PROTEASES; UBIQUITINATION;

EID: 84929591026     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3922     Document Type: Article

References (99)

1. Villamil MA, Liang Q and Zhuang Z. The WD40-repeat protein-containing deubiquitinase complex: catalysis, regulation, and potential for therapeutic intervention. Cell biochemistry and biophysics. 2013; 67:111-126.
2. Blumenfeld N, Gonen H, Mayer A, Smith CE, Siegel NR, Schwartz AL and Ciechanover A. Purification and characterization of a novel species of ubiquitin-carrier protein, E2, that is involved in degradation of non-"Nend rule" protein substrates. The Journal of biological chemistry. 1994; 269:9574-9581.
3. Ciechanover A, Heller H, Elias S, Haas AL and Hershko A. ATP-dependent conjugation of reticulocyte proteins with the polypeptide required for protein degradation. Proceedings of the National Academy of Sciences of the United States of America. 1980; 77:1365-1368.
4. Komander D. The emerging complexity of protein ubiquitination. Biochemical Society transactions. 2009; 37:937-953.
5. Martinez-Forero I, Rouzaut A, Palazon A, Dubrot J and Melero I. Lysine 63 polyubiquitination in immunotherapy and in cancer-promoting inflammation. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009; 15:6751-6757.
6. Kulathu Y and Komander D. Atypical ubiquitylation - the unexplored world of polyubiquitin beyond Lys48 and Lys63 linkages. Nature reviews Molecular cell biology. 2012; 13:508-523.
7. Sowa ME, Bennett EJ, Gygi SP and Harper JW. Defining the Human Deubiquitinating Enzyme Interaction Landscape. Cell. 2009; 138:389-403.
8. Li M, Chen D, Shiloh A, Luo J, Nikolaev AY, Qin J and Gu W. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature. 2002; 416:648-653.
9. Hock AK, Vigneron Am Fau - Carter S, Carter S Fau -Ludwig RL, Ludwig Rl Fau - Vousden KH and Vousden KH. Regulation of p53 stability and function by the deubiquitinating enzyme USP42. EMBO J. 2011; 30:4921-4930.
10. Li M, Brooks CL, Kon N and Gu W. A dynamic role of HAUSP in the p53-Mdm2 pathway. Molecular cell. 2004; 13:879-886.
11. Dirac AM and Bernards R. The deubiquitinating enzyme USP26 is a regulator of androgen receptor signaling. Molecular cancer research : MCR. 2010; 8:844-854.
12. Burska UL, Harle VJ, Coffey K, Darby S, Ramsey H, O'Neill D, Logan IR, Gaughan L and Robson CN. Deubiquitinating enzyme Usp12 is a novel co-activator of the Androgen Receptor. The Journal of biological chemistry. 2013; 288:32641-32650.
13. Joo HY, Jones A, Yang C, Zhai L, Smith ADt, Zhang Z, Chandrasekharan MB, Sun ZW, Renfrow MB, Wang Y, Chang C and Wang H. Regulation of histone H2A and H2B deubiquitination and Xenopus development by USP12 and USP46. The Journal of biological chemistry. 2011; 286:7190-7201.
14. Draker R, Sarcinella E and Cheung P. USP10 deubiquitylates the histone variant H2A.Z and both are required for androgen receptor-mediated gene activation. Nucleic acids research. 2011; 39:3529-3542.
15. Li X, Stevens PD, Yang H, Gulhati P, Wang W, Evers BM and Gao T. The deubiquitination enzyme USP46 functions as a tumor suppressor by controlling PHLPP-dependent attenuation of Akt signaling in colon cancer. Oncogene. 2013; 32:471-478.
16. McClurg UL, Summerscales EE, Harle VJ, Gaughan L and Robson CN. Deubiquitinating enzyme Usp12 regulates the interaction between the androgen receptor and the Akt pathway. Oncotarget. 2014; 5:7081-7092.
17. Zhiqiang Z, Qinghui Y, Yongqiang Z, Jian Z, Xin Z, Haiying M and Yuepeng G. USP1 regulates AKT phosphorylation by modulating the stability of PHLPP1 in lung cancer cells. Journal of cancer research and clinical oncology. 2012; 138:1231-1238.
18. Moretti J, Chastagner P, Liang CC, Cohn MA, Israel A and Brou C. The ubiquitin-specific protease 12 (USP12) is a negative regulator of notch signaling acting on notch receptor trafficking toward degradation. The Journal of biological chemistry. 2012; 287:29429-29441.
19. Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D and Courtois G. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature. 2003; 424:801-805.
20. Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A and Mosialos G. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature. 2003; 424:793-796.
21. Taya S, Yamamoto T, Kanai-Azuma M, Wood SA and Kaibuchi K. The deubiquitinating enzyme Fam interacts with and stabilizes beta-catenin. Genes to cells : devoted to molecular & cellular mechanisms. 1999; 4:757-767.
22. Zhao B, Schlesiger C, Masucci MG and Lindsten K. The ubiquitin specific protease 4 (USP4) is a new player in the Wnt signalling pathway. Journal of cellular and molecular medicine. 2009; 13:1886-1895.
23. Gronbaek K, Hother C and Jones PA. Epigenetic changes in cancer. APMIS. 2007; 115:1039-1059.
24. Stanisic V, Malovannaya A, Qin J, Lonard DM and O'Malley BW. OTU Domain-containing ubiquitin aldehyde-binding protein 1 (OTUB1) deubiquitinates estrogen receptor (ER) alpha and affects ERalpha transcriptional activity. The Journal of biological chemistry. 2009; 284:16135-16145.
25. Faus H, Meyer HA, Huber M, Bahr I and Haendler B. The ubiquitin-specific protease USP10 modulates androgen receptor function. Molecular and cellular endocrinology. 2005; 245:138-146.
26. Zhu P, Zhou W, Wang J, Puc J, Ohgi KA, Erdjument-Bromage H, Tempst P, Glass CK and Rosenfeld MG. A histone H2A deubiquitinase complex coordinating histone acetylation and H1 dissociation in transcriptional regulation. Molecular cell. 2007; 27:609-621.
27. Hasty P and Christy BA. p53 as an intervention target for cancer and aging. Pathobiology of aging & age related diseases. 2013; Oct 8(3).
28. Guseva NV, Rokhlin OW, Bair TB, Glover RB and Cohen MB. Inhibition of p53 expression modifies the specificity of chromatin binding by the androgen receptor. Oncotarget. 2012; 3:183-194.
29. Marouco D, Garabadgiu AV, Melino G and Barlev NA. Lysine-specific modifications of p53: a matter of life and death? Oncotarget. 2013; 4:1556-1571.
30. Thalappilly S, Feng X, Pastyryeva S, Suzuki K, Muruve D, Larocque D, Richard S, Truss M, von Deimling A, Riabowol K and Tallen G. The p53 tumor suppressor is stabilized by inhibitor of growth 1 (ING1) by blocking polyubiquitination. PloS one. 2011; 6:e21065.
31. Sarkari F, Sheng Y and Frappier L. USP7/HAUSP promotes the sequence-specific DNA binding activity of p53. PloS one. 2010; 5:e13040.
32. Sun XX, Challagundla KB and Dai MS. Positive regulation of p53 stability and activity by the deubiquitinating enzyme Otubain 1. EMBO J. 2012; 31:576-592.
33. Li Y, Sun XX, Elferich J, Shinde U, David LL and Dai MS. Monoubiquitination is critical for ovarian tumor domaincontaining ubiquitin aldehyde binding protein 1 (Otub1) to suppress UbcH5 enzyme and stabilize p53 protein. The Journal of biological chemistry. 2014; 289:5097-5108.
34. Sato Y, Yamagata A, Goto-Ito S, Kubota K, Miyamoto R, Nakada S and Fukai S. Molecular basis of Lys-63-linked polyubiquitination inhibition by the interaction between human deubiquitinating enzyme OTUB1 and ubiquitinconjugating enzyme UBC13. The Journal of biological chemistry. 2012; 287:25860-25868.
35. Yagi R, Zhu J and Paul WE. An updated view on transcription factor GATA3-mediated regulation of Th1 and Th2 cell differentiation. International immunology. 2011; 23:415-420.
36. Chou J, Provot S and Werb Z. GATA3 in development and cancer differentiation: cells GATA have it! Journal of cellular physiology. 2010; 222:42-49.
37. Zhang J, Chen C, Hou X, Gao Y, Lin F, Yang J, Gao Z, Pan L, Tao L, Wen C, Yao Z, Tsun A, Shi G and Li B. Identification of the E3 deubiquitinase ubiquitin-specific peptidase 21 (USP21) as a positive regulator of the transcription factor GATA3. The Journal of biological chemistry. 2013; 288:9373-9382.
38. Jung H, Kim BG, Han WH, Lee JH, Cho JY, Park WS, Maurice MM, Han JK, Lee MJ, Finley D and Jho EH. Deubiquitination of Dishevelled by Usp14 is required for Wnt signaling. Oncogenesis. 2013; 2:e64.
39. Wu N, Liu C, Bai C, Han YP, Cho WC and Li Q. Over-Expression of Deubiquitinating Enzyme USP14 in Lung Adenocarcinoma Promotes Proliferation through the Accumulation of beta-Catenin. International journal of molecular sciences. 2013; 14:10749-10760.
40. Zhang XY, Varthi M, Sykes SM, Phillips C, Warzecha C, Zhu W, Wyce A, Thorne AW, Berger SL and McMahon SB. The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Molecular cell. 2008; 29:102-111.
41. Glinsky GV. Genomic models of metastatic cancer:functional analysis of death-from-cancer signature genes reveals aneuploid, anoikis-resistant, metastasis-enabling phenotype with altered cell cycle control and activated Polycomb Group (PcG) protein chromatin silencing pathway. Cell cycle (Georgetown, Tex). 2006; 5:1208-1216.
42. Liu YL, Yang YM, Xu H and Dong XS. Aberrant expression of USP22 is associated with liver metastasis and poor prognosis of colorectal cancer. Journal of surgical oncology. 2011; 103:283-289.
43. Joo HY, Zhai L, Yang C, Nie S, Erdjument-Bromage H, Tempst P, Chang C and Wang H. Regulation of cell cycle progression and gene expression by H2A deubiquitination. Nature. 2007; 449:1068-1072.
44. Xu Y, Yang H, Joo HY, Yu JH, Smith ADt, Schneider D, Chow LT, Renfrow M and Wang H. Ubp-M serine 552 phosphorylation by cyclin-dependent kinase 1 regulates cell cycle progression. Cell cycle (Georgetown, Tex). 2013; 12:3219-3227.
45. Yang W, Lee YH, Jones AE, Woolnough JL, Zhou D, Dai Q, Wu Q, Giles KE, Townes TM and Wang H. The histone H2A deubiquitinase Usp16 regulates embryonic stem cell gene expression and lineage commitment. Nature communications. 2014; 5:3818.
46. Burma S, Chen BP, Murphy M, Kurimasa A and Chen DJ. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. The Journal of biological chemistry. 2001; 276(45):462-467.
47. Stiff T, O'Driscoll M, Rief N, Iwabuchi K, Lobrich M and Jeggo PA. ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer research. 2004; 64:2390-2396.
48. Li T, Guan J, Huang Z, Hu X and Zheng X. RNF168-mediated H2A neddylation antagonizes ubiquitylation of H2A and regulates DNA damage repair. Journal of cell science. 2014; 127:2238-2248.
49. Sharma N, Zhu Q, Wani G, He J, Wang QE and Wani AA. USP3 counteracts RNF168 via deubiquitinating H2A and gammaH2AX at lysine 13 and 15. Cell cycle (Georgetown, Tex). 2014; 13:106-114.
50. Nakagawa T, Kajitani T, Togo S, Masuko N, Ohdan H, Hishikawa Y, Koji T, Matsuyama T, Ikura T, Muramatsu M and Ito T. Deubiquitylation of histone H2A activates transcriptional initiation via trans-histone cross-talk with H3K4 di-and trimethylation. Genes & development. 2008; 22:37-49.
51. Mosbech A, Lukas C, Bekker-Jensen S and Mailand N. The deubiquitylating enzyme USP44 counteracts the DNA double-strand break response mediated by the RNF8 and RNF168 ubiquitin ligases. The Journal of biological chemistry. 2013; 288:16579-16587.
52. Zhang Z, Jones A, Joo HY, Zhou D, Cao Y, Chen S, Erdjument-Bromage H, Renfrow M, He H, Tempst P, Townes TM, Giles KE, Ma L and Wang H. USP49 deubiquitinates histone H2B and regulates cotranscriptional pre-mRNA splicing. Genes & development. 2013; 27:1581-1595.
53. Hock AK, Vigneron AM and Vousden KH. Ubiquitinspecific peptidase 42 (USP42) functions to deubiquitylate histones and regulate transcriptional activity. The Journal of biological chemistry. 2014; 289:34862-34870.
54. van der Knaap JA, Kumar BR, Moshkin YM, Langenberg K, Krijgsveld J, Heck AJ, Karch F and Verrijzer CP. GMP synthetase stimulates histone H2B deubiquitylation by the epigenetic silencer USP7. Molecular cell. 2005; 17:695-707.
55. Cohn MA, Kee Y, Haas W, Gygi SP and D'Andrea AD. UAF1 is a subunit of multiple deubiquitinating enzyme complexes. The Journal of biological chemistry. 2009; 284:5343-5351.
56. Kee Y, Yang K, Cohn MA, Haas W, Gygi SP and D'Andrea AD. WDR20 regulates activity of the USP12 x UAF1 deubiquitinating enzyme complex. The Journal of biological chemistry. 2010; 285:11252-11257.
57. Zhang XY, Pfeiffer HK, Thorne AW and McMahon SB. USP22, an hSAGA subunit and potential cancer stem cell marker, reverses the polycomb-catalyzed ubiquitylation of histone H2A. Cell cycle (Georgetown, Tex). 2008; 7:1522-1524.
58. Cole AJ, Clifton-Bligh RJ and Marsh DJ. Ubiquitination and cancer: Histone H2B monoubiquitination - roles to play in human malignancy. Endocrine-related cancer. 2014; 22:19-33.
59. Aressy B, Jullien D, Cazales M, Marcellin M, Bugler B, Burlet-Schiltz O and Ducommun B. A screen for deubiquitinating enzymes involved in the G(2)/M checkpoint identifies USP50 as a regulator of HSP90-dependent Wee1 stability. Cell cycle (Georgetown, Tex). 2010; 9:3815-3822.
60. Atanassov BS, Evrard YA, Multani AS, Zhang Z, Tora L, Devys D, Chang S and Dent SY. Gcn5 and SAGA regulate shelterin protein turnover and telomere maintenance. Molecular cell. 2009; 35:352-364.
61. Lin Z, Yang H, Kong Q, Li J, Lee SM, Gao B, Dong H, Wei J, Song J, Zhang DD and Fang D. USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development. Molecular cell. 2012; 46:484-494.
62. Ding F, Bao C, Tian Y, Xiao H, Wang M, Xie X, Hu F and Mei J. USP22 Promotes NSCLC Tumorigenesis via MDMX Up-Regulation and Subsequent p53 Inhibition. International journal of molecular sciences. 2014; 16:307-320.
63. Huang TT, Nijman SM, Mirchandani KD, Galardy PJ, Cohn MA, Haas W, Gygi SP, Ploegh HL, Bernards R and D'Andrea AD. Regulation of monoubiquitinated PCNA by DUB autocleavage. Nature cell biology. 2006; 8:339-347.
64. Williams SA, Maecker HL, French DM, Liu J, Gregg A, Silverstein LB, Cao TC, Carano RA and Dixit VM. USP1 deubiquitinates ID proteins to preserve a mesenchymal stem cell program in osteosarcoma. Cell. 2011; 146:918-930.
65. Kim JM, Parmar K, Huang M, Weinstock DM, Ruit CA, Kutok JL and D'Andrea AD. Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype. Developmental cell. 2009; 16:314-320.
66. Park E, Kim JM, Primack B, Weinstock DM, Moreau LA, Parmar K and D'Andrea AD. Inactivation of Uaf1 causes defective homologous recombination and early embryonic lethality in mice. Molecular and cellular biology. 2013; 33:4360-4370.
67. Yuan J, Luo K, Zhang L, Cheville JC and Lou Z. USP10 regulates p53 localization and stability by deubiquitinating p53. Cell. 2010; 140:384-396.
68. Zhang D, Zaugg K, Mak TW and Elledge SJ. A role for the deubiquitinating enzyme USP28 in control of the DNAdamage response. Cell. 2006; 126:529-542.
69. Takahashi M, Higuchi M, Matsuki H, Yoshita M, Ohsawa T, Oie M and Fujii M. Stress granules inhibit apoptosis by reducing reactive oxygen species production. Molecular and cellular biology. 2013; 33:815-829.
70. Khoronenkova SV, Dianova, II, Ternette N, Kessler BM, Parsons JL and Dianov GL. ATM-dependent downregulation of USP7/HAUSP by PPM1G activates p53 response to DNA damage. Molecular cell. 2012; 45:801-813.
71. Edelmann MJ, Kramer HB, Altun M and Kessler BM. Posttranslational modification of the deubiquitinating enzyme otubain 1 modulates active RhoA levels and susceptibility to Yersinia invasion. The FEBS journal. 2010; 277:2515-2530.
72. Kouranti I, McLean JR, Feoktistova A, Liang P, Johnson AE, Roberts-Galbraith RH and Gould KL. A global census of fission yeast deubiquitinating enzyme localization and interaction networks reveals distinct compartmentalization profiles and overlapping functions in endocytosis and polarity. PLoS Biol. 2010; 8:e1000471.
73. Villamil MA, Liang Q, Chen J, Choi YS, Hou S, Lee KH and Zhuang Z. Serine phosphorylation is critical for the activation of ubiquitin-specific protease 1 and its interaction with WD40-repeat protein UAF1. Biochemistry. 2012; 51:9112-9123.
74. Cotto-Rios XM, Jones MJ and Huang TT. Insights into phosphorylation-dependent mechanisms regulating USP1 protein stability during the cell cycle. Cell cycle (Georgetown, Tex). 2011; 10:4009-4016.
75. Cataldo F, Peche LY, Klaric E, Brancolini C, Myers MP, Demarchi F and Schneider C. CAPNS1 regulates USP1 stability and maintenance of genome integrity. Molecular and cellular biology. 2013; 33:2485-2496.
76. Mahul-Mellier AL, Datler C, Pazarentzos E, Lin B, Chaisaklert W, Abuali G and Grimm S. De-ubiquitinating proteases USP2a and USP2c cause apoptosis by stabilising RIP1. Biochimica et biophysica acta. 2012; 1823:1353-1365.
77. Liu J, Xia H, Kim M, Xu L, Li Y, Zhang L, Cai Y, Norberg HV, Zhang T, Furuya T, Jin M, Zhu Z, Wang H, Yu J, Li Y, Hao Y, et al. Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell. 2011; 147:223-234.
78. Xiong J, Xu X, Zhou X, Liu J, Gong Z, Wu P and Li W. USP22 transcriptional activity is negatively regulated by the histone deacetylase inhibitor trichostatin A. Molecular medicine reports. 2014; 10:3343-3347.
79. Faesen AC, Dirac AM, Shanmugham A, Ovaa H, Perrakis A and Sixma TK. Mechanism of USP7/HAUSP activation by its C-terminal ubiquitin-like domain and allosteric regulation by GMP-synthetase. Molecular cell. 2011; 44:147-159.
80. Piatkov KI, Colnaghi L, Bekes M, Varshavsky A and Huang TT. The auto-generated fragment of the Usp1 deubiquitylase is a physiological substrate of the N-end rule pathway. Molecular cell. 2012; 48:926-933.
81. Wiener R, DiBello AT, Lombardi PM, Guzzo CM, Zhang X, Matunis MJ and Wolberger C. E2 ubiquitin-conjugating enzymes regulate the deubiquitinating activity of OTUB1. Nature structural & molecular biology. 2013; 20:1033-1039.
82. Zhen Y, Knobel PA, Stracker TH and Reverter D. Regulation of USP28 deubiquitinating activity by SUMO conjugation. The Journal of biological chemistry. 2014; 289:34838-34850.
83. Okuda H, Ohdan H, Nakayama M, Koseki H, Nakagawa T and Ito T. The USP21 short variant (USP21SV) lacking NES, located mostly in the nucleus in vivo, activates transcription by deubiquitylating ubH2A in vitro. PloS one. 2013; 8:e79813.
84. Ke Q, Ellen TP and Costa M. Nickel compounds induce histone ubiquitination by inhibiting histone deubiquitinating enzyme activity. Toxicology and applied pharmacology. 2008; 228:190-199.
85. D'Arcy P and Linder S. Molecular pathways: translational potential of deubiquitinases as drug targets. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014; 20:3908-3914.
86. Faesen Alex C, Luna-Vargas Mark PA, Geurink Paul P, Clerici M, Merkx R, van Dijk Willem J, Hameed Dharjath S, El Oualid F, Ovaa H and Sixma Titia K. The differential modulation of USP activity by internal regulatory domains, interactors and eight ubiquitin chain types. Chemistry & biology. 2011; 18:1550-1561.
87. Chen J, Dexheimer TS, Ai Y, Liang Q, Villamil MA, Inglese J, Maloney DJ, Jadhav A, Simeonov A and Zhuang Z. Selective and cell-active inhibitors of the USP1/UAF1 deubiquitinase complex reverse cisplatin resistance in nonsmall cell lung cancer cells. Chemistry & biology. 2011; 18:1390-1400.
88. Liang Q, Dexheimer TS, Zhang P, Rosenthal AS, Villamil MA, You C, Zhang Q, Chen J, Ott CA, Sun H, Luci DK, Yuan B, Simeonov A, Jadhav A, Xiao H, Wang Y, et al. A selective USP1-UAF1 inhibitor links deubiquitination to DNA damage responses. Nature chemical biology. 2014; 10:298-304.
89. Dexheimer TS, Rosenthal AS, Luci DK, Liang Q, Villamil MA, Chen J, Sun H, Kerns EH, Simeonov A, Jadhav A, Zhuang Z and Maloney DJ. Synthesis and structure-activity relationship studies of N-benzyl-2-phenylpyrimidin-4-amine derivatives as potent USP1/UAF1 deubiquitinase inhibitors with anticancer activity against nonsmall cell lung cancer. Journal of medicinal chemistry. 2014; 57:8099-8110.
90. Dexheimer TS, Rosenthal AS, Liang Q, Chen J, Villamil MA, Kerns EH, Simeonov A, Jadhav A, Zhuang Z and Maloney DJ. (2010). Discovery of ML323 as a Novel Inhibitor of the USP1/UAF1 Deubiquitinase Complex. Probe Reports from the NIH Molecular Libraries Program. (Bethesda MD: NIH Molecular Libraries Programme).
91. Mistry H, Hsieh G, Buhrlage SJ, Huang M, Park E, Cuny GD, Galinsky I, Stone RM, Gray NS, D'Andrea AD and Parmar K. Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells. Molecular cancer therapeutics. 2013; 12:2651-2662.
92. Nicholson B and Suresh Kumar KG. The multifaceted roles of USP7: new therapeutic opportunities. Cell biochemistry and biophysics. 2011; 60:61-68.
93. Reverdy C, Conrath S, Lopez R, Planquette C, Atmanene C, Collura V, Harpon J, Battaglia V, Vivat V, Sippl W and Colland F. Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme. Chemistry & biology. 2012; 19:467-477.
94. Lill JR and Wertz IE. Toward understanding ubiquitinmodifying enzymes: from pharmacological targeting to proteomics. Trends in pharmacological sciences. 2014; 35:187-207.
95. Chauhan D, Tian Z, Nicholson B, Kumar KG, Zhou B, Carrasco R, McDermott JL, Leach CA, Fulcinniti M, Kodrasov MP, Weinstock J, Kingsbury WD, Hideshima T, Shah PK, Minvielle S, Altun M, et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer cell. 2012; 22:345-358.
96. Fan YH, Cheng J, Vasudevan SA, Dou J, Zhang H, Patel RH, Ma IT, Rojas Y, Zhao Y, Yu Y, Zhang H, Shohet JM, Nuchtern JG, Kim ES and Yang J. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis. Cell death & disease. 2013; 4:e867.
97. Altun M, Kramer HB, Willems LI, McDermott JL, Leach CA, Goldenberg SJ, Kumar KG, Konietzny R, Fischer R, Kogan E, Mackeen MM, McGouran J, Khoronenkova SV, Parsons JL, Dianov GL, Nicholson B, et al. Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes. Chemistry & biology. 2011; 18:1401-1412.
98. D'Arcy P, Brnjic S, Olofsson MH, Fryknas M, Lindsten K, De Cesare M, Perego P, Sadeghi B, Hassan M, Larsson R and Linder S. Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med. 2011; 17:1636-1640.
99. Zhou B, Zuo Y, Li B, Wang H, Liu H, Wang X, Qiu X, Hu Y, Wen S, Du J and Bu X. Deubiquitinase inhibition of 19S regulatory particles by 4-arylidene curcumin analog AC17 causes NF-kappaB inhibition and p53 reactivation in human lung cancer cells. Molecular cancer therapeutics. 2013; 12:1381-1392.